May 24 marks World Schizophrenia Day, a moment to recognize the profound impact of schizophrenia on individuals, carers, and communities. Severe mental illness can threaten the very essence of who we are, reshaping lives in ways that are not always seen or fully understood by others. Could more be done? Read the new POLITICO Europe article, supported and funded by Teva, which draws on recent patient and carer insights to explore why change in schizophrenia care is critically needed: https://ow.ly/4HSP50Z2yus At Teva, we are committed to advancing innovation in neuroscience, addressing unmet needs, delivering with scale, speed and precision. #WorldSchizophreniaDay #TevaNeuroscience #Stigma
Om os
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
- Websted
-
http://www.tevapharm.com
Eksternt link til Teva Pharmaceuticals
- Branche
- Produktion af lægemidler
- Virksomhedsstørrelse
- Over 10.001 medarbejdere
- Hovedkvarter
- Tel-Aviv
- Type
- Aktieselskab
- Specialer
- generic medicines, specialty medicines, CNS, active pharmaceutical ingredients, respiratory, biosimilars, biologics, pain care, migraine og oncology
Beliggenheder
Medarbejdere hos Teva Pharmaceuticals
Opdateringer
-
Teva Pharmaceuticals genopslog dette
An exciting moment for our neuroscience pipeline. Today marks an important step in our commitment to support people living with schizophrenia. The European Medicines Agency has accepted Teva’s Marketing Authorization Application for our investigational long-acting injectable olanzapine treatment. This milestone reflects what careful science, strong collaboration, and steady execution can achieve. It also highlights our commitment to advancing potential treatment options in areas where the need remains high. Thank you to the patients and investigators who participate in clinical trials, and to the Teva Pharmaceuticals colleagues whose expertise, care, and persistence have helped bring us to this point. Read more here: https://bit.ly/3ReFjns #Neuroscience #TevaRnD
-
-
One harmful misconception of #schizophrenia is that people living with the condition are inherently withdrawn or prefer isolation. The reality is starkly different: social isolation is often a primary barrier to recovery. This disconnect exacerbates symptoms and increases risk of relapses. Listening to advocates and community partners on the unmet need in schizophrenia helped us to establish Home Ground™ Schizophrenia Community, a centralized destination delivering tailored resources to foster connection, reduce barriers to care, and champion a more inclusive understanding of mental health. Ahead of #WorldSchizophreniaDay this Sunday, let’s come together to support people living with this complex condition and their care partners. Discover more at HomeGroundSCZ.com #BeyondWhatYouSee #MentalHealthAwarenessMonth #TevaPharm
-
Earlier this year, we were proud to launch a powerful educational campaign to shine a light on #HuntingtonsDisease (HD) and build vital support for the community affected by this devastating condition. One of the more visible, yet often misunderstood symptoms of HD is chorea, or involuntary movements. Honestly HD Ambassadors Will Forte and his brother-in-law Doug, the latter who has been living with HD chorea, speak passionately on the importance of talking openly about HD diagnosis to help raise awareness and support for others living with HD. To learn more about the campaign, visit https://ow.ly/xSFl50Z1CIm #HDAwareness #HDAwarenessMonth #PatientStories
-
Teva Pharmaceuticals genopslog dette
A chronic condition isn’t just something you have. It’s something you manage in every decision you make. Inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn’s disease are no exception. They impact far more than physical health for the millions of people managing these conditions. They affect daily life, work, families, and the ability to plan with confidence. While our role in Teva Global Operations (TGO) is not always visible, it’s foundational. Every batch produced, process optimized, and quality standard upheld is part of a larger commitment to ensuring patients can rely on consistent access to effective treatments. That work is delivered every day across our global manufacturing network, including teams in multiple countries, supporting treatments for patients living with IBD. On this World IBD Day, I’m reminded of the patients who depend on us to improve their conditions and their quality of daily life. This is what drives us to chase excellence and do the work right, every day. #WorldIBDDay #IBD #UlcerativeColitis #CrohnsDisease #TevaPharm
-
-
Around 4.9 million people worldwide live with inflammatory bowel disease (#IBD), with cases steadily rising, particularly in Western countries. IBD is a chronic inflammatory condition that affects the digestive system, referring primarily to two conditions, ulcerative colitis and Crohn’s disease. There is currently no cure for IBD. While several treatment options are available, they may not all work for every patient, or may stop working over time. This #WorldIBDDay, we invite you to swipe through and learn more about this condition. 👇
-
Teva Pharmaceuticals genopslog dette
Big News: We are now Investment Grade. I’m thrilled to share that Fitch Ratings has raised Teva Pharmaceuticals credit rating to Investment Grade (BBB-, Stable Outlook). This milestone, Teva’s third upgrade from Fitch in less than two years, underscores the magnitude of Teva’s transformation and #PivotToGrowth strategy execution, confidence in our growing financial flexibility, and the continued transition toward a higher‑margin innovative and biosimilar portfolio. What an incredible testament to our journey to becoming a high-velocity biopharma company. It speaks volumes about our unwavering commitment to reducing debt, strengthening our balance sheet, generating sustainable cash flow, and driving Teva forward with momentum. Expressing deep gratitude to our dedicated teams across Teva for their tireless and fantastic work. The energy behind our innovative pipeline is real, and the potential opportunities ahead are even greater as we build a stronger competitive edge. The future is ours to shape - and we’re moving forward with speed, purpose and conviction. Amit Hazan Christopher S. Efi Benmeir Sharon Barber-Lui Roee Zetland #CreditRating #FinanceLeadership #PivotToGrowth #ValueCreation
-
-
Around 1 in 100 people worldwide live with celiac disease. It’s a genetic autoimmune condition triggered by gluten, and its impact goes beyond digestion, with symptoms that can affect multiple systems in the body. Diagnosis can be complex, and management requires a strict, long-term dietary approach. Swipe through for key facts 👇
-
We understand the significant impact that conditions like schizophrenia and bipolar disorder have on patients, their loved ones, and their communities. That’s why mental health is one of our top priorities at Teva. Explore our key therapeutic areas here: https://ow.ly/3iMl50YYVbe
-
Tilknyttede sider
Tilsvarende sider
Finansiering
Teva Pharmaceuticals
4 runder i alt
Læs mere på crunchbase
Seneste runde
Post IPO-gæld
Eksternt Crunchbase-link til seneste finansieringsrunde
2.300.000.000,00 US$